Refine by
Cardiac Device Articles & Analysis
40 news found
Implicity, a leader in remote patient monitoring and cardiac data management solutions, announced it has joined the Amazon Web Services (AWS) Independent Software Vendor (ISV) Accelerate Program, a co-sell program for AWS partners that provide software solutions that run on or integrate with AWS. ...
Valo Health, Inc (“Valo”) shared the initial results of a collaborative study with the U.S. Food and Drug Administration (FDA), demonstrating the potential of Valo’s Biowire platform to predict clinical efficacy of Cardiac Contractility Modulation ...
(NASDAQ:BTCY) (“Biotricity” or the “Company”), a medical diagnostic and consumer healthcare technology company, today announced a significant milestone of recording and analyzing over 2 billion heartbeats for Atrial Fibrillation (AFib), the most common type of cardiac arrhythmia and a leading cause of stroke. Bioflux®, Biotricity’s ...
Cardiac arrhythmias affect not only adults, but unfortunately also children struggle with such health problems. ...
Bioflux-AI combines an FDA-approved, high-precision, small mobile cardiac telemetry (MCT) device with AI-driven algorithms specifically trained for the prediction of stroke in stage 4 and stage 5 CKD patients. ...
iRhythm Technologies has presented new data on its Zio wearable cardiac monitoring device at the American College of Cardiology (ACC) 71st Annual Scientific Session & Expo, building the clinical case for its devices. One study used Zio AT for monitoring patients who were taken to hospital after fainting. By using the ...
In this Roll-in cohort there were no procedure- or device-related major adverse cardiac or neurological events. After 12 months, patients with moderate or severely reduced left ventricular ejection fraction (LVEF) had significantly improved LVEF by 4.69.3 (p=0.008) absolute % as compared to baseline prior to shunt implantation. ...
(NASDAQ:BTCY) (“Biotricity” or the “Company”), a medical diagnostic and consumer healthcare technology company, will officially launch the commercial sales of its FDA cleared, wireless wearable cardiac monitoring device, Biotres, in April 2022. The product has been available for pre-orders to physicians, medical offices, hospitals and ...
Rickbeil wondered if Sheldon might be a candidate for a WATCHMAN device to reduce the risk. WATCHMAN, a one-time procedural implant, can be placed within the LAA, permanently closing it off and removing the greatest source of clot formation and cause of stroke in patients with AFib. ...
(NASDAQ:BTCY) (“Biotricity” or the “Company”), a medical diagnostic and consumer healthcare technology company, today announced that it is now taking pre-orders for Biotres, the Company’s three-lead device designed to continuously record electro-cardiogram (ECG) data for early detection of cardiac arrhythmias. The Company believes ...
Biotres is designed to continuously record ECG data for early detection of cardiac arrhythmias The Biotres addresses the $2 Billion-dollar holter market Biotricity Inc. ...
Many patients with heart failure require cardiac resynchronization therapy (CRT), which uses lead-based cardiac pacing devices to coordinate the beating of the left and right sides of the heart. ...
Dr Steinhaus has extensive clinical and business experience in cardiac rhythm management, including performing numerous clinical studies in implantable cardiac devices and leads. ...
During his 30-year career, he has acquired a unique expertise in implantable cardiac devices. Former VP RAQACA of CardiAQ Valve Technologies, a transcatheter valve start-up acquired by Edwards Lifesciences for $350 million, he has also developed an extensive knowledge of cardiac assist devices (first at Arrow, then at Abbott as a ...
ByCorWave
CorWave announced that it successfully completed its first 60-day preclinical study to evaluate its Left Ventricular Assist Device (LVAD). The results were presented at the 46th Annual Conference of the European Society for Artificial Organs (ESAO) in Hannover. ...
ByCorWave
South Korean artificial intelligence (AI) developer, VUNO Inc. announced today that it has received regulatory approval from the Ministry of Food and Drug Safety (MFDS) for its VUNO Med®–DeepCARS™, an AI medical device for cardiac arrest prediction through vital signs. VUNO Med®–DeepCARS™ is a breakthrough AI-driven medical ...
The company also announced the FDA approval of its Investigational Device Exemption (IDE) application to conduct a clinical trial of a novel cardiac arrest treatment indication. ...
Harild brings significant medical device experience to the team. “I am thrilled to join the board of directors at Neurescue to help advance its next-generation balloon catheter technology in development, which has the potential to save the lives of the millions of people worldwide suffering from cardiac arrest each year,” said Mette-Marie Harild. ...
Gordon Ho, at American College of Cardiology 2021 and the Taiwan Heart Rhythm Society 2021 (THRS), the research won first prize in the “Clinical - Ventricular Arrhythmias/Cardiac Implanted Electronic Device” category at THRS. As stated at the ACC and THRS conferences, the study concluded that the simplified, non-invasive workflow, involving ...
Bluegrass Vascular Technologies, a private medical technology company focused on innovating lifesaving devices and methods for vascular access procedures, announced today the publication of a report documenting the clinical utility of the Surfacer System to gain venous access prior to the placement of cardiac resynchronization therapy (CRT) ...